Natalie L. Kingston

Washington University in St. Louis — United States

Immunology and Microbiology · Life Sciences

11h-index702citations121works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(34), Cancer Immunotherapy and Biomarkers(33), Phagocytosis and Immune Regulation(29), Cytokine Signaling Pathways and Interactions(23), Brain Metastases and Treatment(16)

Publications121 total

Supplementary Table 3 from Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer
2025Open Access
Supplementary Table 1 from Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer
2025Open Access
Supplementary Figures from Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer
2025Open Access
Supplementary Table 2 from Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer
2025Open Access
Supplementary Table S9 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S3 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S8 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Figures from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S5 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S7 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S6 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S2 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S4 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S1 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Combined Flt3L and CD40 agonism restores dendritic cell–driven T cell immunity in pancreatic cancer
Science Immunology·2025· 6 cited
KDM4C inhibition blocks tumor growth in basal breast cancer by promoting cathepsin L-mediated histone H3 cleavage
Nature Genetics·2025· 4 citedOpen Access
Supplementary Table 3 from Systemic Alterations in Type-2 Conventional Dendritic Cells Leads to Impaired Tumor Immunity in Pancreatic Cancer
2024Open Access
Supplementary Figures from Systemic Alterations in Type-2 Conventional Dendritic Cells Leads to Impaired Tumor Immunity in Pancreatic Cancer
2024Open Access
Supplementary Table 2 from Systemic Alterations in Type-2 Conventional Dendritic Cells Leads to Impaired Tumor Immunity in Pancreatic Cancer
2024Open Access
Supplementary Table 3 from Systemic Alterations in Type-2 Conventional Dendritic Cells Leads to Impaired Tumor Immunity in Pancreatic Cancer
2024Open Access
page 1 of 7Next →

Frequent Co-authors

Graham D. Hogg(25), David G. DeNardo(25), Brett L. Knolhoff(22), John Baer(21), Kornélia Polyák(20), Varintra E. Lander(20), Liang‐I Kang(20), Nicholas W. Harper(18), Guillermo Peluffo(18), Anne Trinh(17), Franziska Michor(16), Laura E. Stevens(16), Bojana Jovanović(16), Ryan C. Fields(14), William G. Hawkins(14), Maša Alečković(13), Xintao Qiu(13), Daniel Temko(13), Zheqi Li(13), Shawn B. Egri(13)